Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis

Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis

Abstract Background Treatment of relapsed or refractory primary CNS lymphoma (r/r PCNSL) is difficult, particularly in patients not eligible for high dose chemotherapy with autologous stem cell transplantation (HDC-ASCT). No standard treatment has been defined for these patients yet. Methods We retr...

Full description

Bibliographic Details
Main Authors: Sabine Seidel, Thomas Kowalski, Verena Nilius-Eliliwi, Roland Schroers, Uwe Schlegel
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Neurological Research and Practice
Subjects:
r/r PCNSL
Primary CNS lymphoma
Salvage treatment
Relapse
High-dose methotrexate
Temozolomide
Online Access:https://doi.org/10.1186/s42466-023-00234-y

Internet

https://doi.org/10.1186/s42466-023-00234-y

Similar Items